Patients with inflammatory bowel disease, especially those on immunosuppressive 
therapy, are at higher risk of acquiring infectious diseases (Reich et al., 
2016). For this reason, immunizations are routinely recommended in comprehensive 
inflammatory bowel disease care. SHINGRIX, a non-live recombinant herpes zoster 
vaccine, was approved by the Food and Drug Administration in 2017. Adults aged 
50 and over are recommended to receive two doses of SHINGRIX. Unlike ZOSTAVAX® 
which is a live zoster vaccine that has been in use since 2006, SHINGRIX is safe 
for those on immunosuppression (Reich et al., 2016). The offside effects of 
SHINGRIX include injection-site erythema, tenderness, fatigue, and 
gastrointestinal upset. To our knowledge, blistering autoimmune skin disorders 
following SHINGRIX administration have not been reported. Here we discuss a case 
of a 74-year-old female patient with a history of ulcerative proctosigmoiditis 
on mesalamine who presented with a blistering skin disease after each SHINGRIX 
vaccination.